Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50%

Kılıçkap, SaadettinÖzgüroğlu, MustafaSezer, AhmetGümüş, MahmutBondarenko, IgorGogishvili, MirandaTurk, Haci M.2025-06-032025-06-032024Kilickap, S., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., ... & Magnan, H. (2024). OA11. 06 Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression≥ 50%: 5-y Outcomes of EMPOWER-Lung 1. Journal of Thoracic Oncology, 19(10), S35.1556-08641556-1380https://hdl.handle.net/20.500.12713/7284Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50%eninfo:eu-repo/semantics/closedAccessAdvanced NSCLCBrain MetastasesCemiplimabImmunotherapyPD-L1Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50%Other19103535WOS:0013379256000542-s2.0-105004431788Q1Q1